相关实验视频

Updated: Jan 13, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

乳腺癌的SMC6表达和结果

Flavia Regina Rotea Mangone^1,2, Ana Cristina Victorino Krepischi³, Ana Carolina Pavanelli^1,2

¹Department of Radiology and Oncology, Laboratory of Molecular Genetics, Centro de Investigação Translacionalem Oncologia- CTO, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.

The Indian journal of medical research

|January 11, 2026

概括

乳腺癌中SMC6蛋白表达可能表明遗传不稳定,并影响患者的预后. 较低的SMC6表达与更好的结果相关,表明其作为复发风险生物标志物的潜力.

科学领域:

遗传学遗传学是一种遗传学.
在瘤学瘤学.
分子生物学分子生物学

背景情况:

基因不稳定性在瘤中很常见,可能与同源重组 (HR) 修复途径失衡有关.
HR对于DNA双链断裂 (DSB) 修复和保持基因组稳定性至关重要.
在DSB修复中,SMC6复合体 (与SMC5一起) 起作用.

研究的目的:

研究SMC6表达,基因组不稳定性和乳腺癌预后之间的关系.
评估SMC6作为非BRCA1/BRCA2突变乳腺癌患者的潜在生物标志物.

主要方法:

对33名乳腺癌患者 (非携带BRCA1/BRCA2突变的患者) 的观察后期队列研究.
在组织微阵列 (481个样本) 上通过qRT-PCR评估SMC6表达和蛋白质水平 (SMC6low vs. SMC6high).
使用全基因组比较基因组杂交分析复制数变异 (CNV).

主要成果:

SMC6低瘤呈现出更高的副本数变异 (CNV).
更高的SMC6蛋白表达 (SMC6high) 与较差的无病生存率有关,特别是在光线亚型中.
在雌激素受体阳性 (ERpos) 瘤中,SMC6的低表达是防止复发的保护性生物标志物.

结论:

SMC6表达可能与乳腺癌复发有关.
异常的SMC6表达可能意味着瘤遗传不稳定.
SMC6表达水平可以作为乳腺癌复发的预后生物标志物.

关键词:

生物标志物生物标志物在SMC6中使用.乳腺癌乳腺癌乳腺癌表达方式表达方式表达方式基因组的不稳定性预后预后预后

更多相关视频

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频